Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Capsaicin
Drug ID BADD_D00353
Description Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.
Indications and Usage The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.
Marketing Status approved
ATC Code M02AB01; N01BX04
DrugBank ID DB06774
KEGG ID D00250
MeSH ID D002211
PubChem ID 1548943
TTD Drug ID D0U5CE
NDC Product Code 73102-046; 83158-387; 24286-1559; 45865-773; 49671-001; 49671-002; 59779-381; 68016-067; 69420-6025; 70656-742; 71480-831; 72490-018; 72490-023; 72490-026; 72512-929; 79643-002; 66499-0036; 11822-7448; 50268-195; 50488-1075; 50488-2025; 59088-310; 0363-9902; 69420-7025; 0536-2525; 72490-024; 72512-928; 75249-006; 51686-0002; 41167-7514; 49873-608; 51672-5308; 59316-996; 63187-660; 69842-313; 0536-1118; 70583-733; 71178-777; 72490-032; 72490-037; 53943-904; 59088-479; 72490-014; 72490-028; 72490-029; 72490-033; 72490-034; 72512-930; 81877-515; 50268-198; 52099-8005; 61787-443; 62742-4216; 63868-308; 71073-208; 71178-776; 73102-117; 73141-559; 73287-018; 75249-003; 17353-0010; 10742-8127; 11993-001; 35192-040; 59088-433; 59779-770; 65923-123; 72490-010; 72490-022; 72490-035; 72490-039; 72683-003; 72683-006; 73486-100; 49452-1321; 51686-0003; 62991-3129; 11993-000; 35192-023; 41250-842; 46122-753; 46581-700; 50268-197; 55264-110; 70000-0556; 71659-842; 72490-036; 73454-001; 82345-855; 59568-9200; 50488-1025; 61787-556; 70656-741; 72490-025; 72490-027; 72490-030; 73557-180; 82777-001; 51824-094; 55614-410; 0363-0837; 67510-0303; 68071-3430; 0536-1264; 71101-904; 72490-019; 81533-200; 51927-1807; 81961-001; 49035-890; 50488-1060; 69396-103; 70000-0549; 72490-012; 72490-013; 72490-021; 72847-316; 82531-001; 51552-0129; 11822-4210; 42903-008; 50268-196; 52000-040
UNII S07O44R1ZM
Synonyms Capsaicin | Capsaicine | 8-Methyl-N-Vanillyl-6-Nonenamide | 8 Methyl N Vanillyl 6 Nonenamide | Antiphlogistine Rub A-535 Capsaicin | Axsain | Zacin | Capsidol | Zostrix | Capzasin | Gelcen | Katrum | NGX-4010 | NGX 4010 | NGX4010 | Capsicum Farmaya | Capsin
Chemical Information
Molecular Formula C18H27NO3
CAS Registry Number 404-86-4
SMILES CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Application site anaesthesia08.02.01.017; 12.07.01.017; 17.02.06.010---
Application site erythema08.02.01.001; 12.07.01.001; 23.03.06.005---
Application site irritation08.02.01.003; 12.07.01.003---
Application site oedema08.02.01.020; 12.07.01.020---
Application site pain08.02.01.004; 12.07.01.004---
Application site pruritus08.02.01.005; 12.07.01.005; 23.03.12.004---
Application site rash08.02.01.016; 12.07.01.016; 23.03.13.008---
Application site reaction08.02.01.006; 12.07.01.006---
Application site warmth08.02.01.029; 12.07.01.029---
Blood pressure increased13.14.03.005---
Bronchitis11.01.09.001; 22.07.01.001--
Burning sensation08.01.09.029; 17.02.06.001---
Burns second degree12.05.04.003; 23.03.11.028---
Cough22.02.03.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dysgeusia07.14.03.001; 17.02.07.003--
Erythema23.03.06.001---
Eye disorder06.08.03.001---
Eye irritation06.04.05.003---
Eye pain06.08.03.002--
Gastrointestinal disorder07.11.01.001---
Headache17.14.01.001--
Herpes zoster11.05.02.003; 17.09.03.026; 23.11.05.005--
Hyperaesthesia17.02.06.004; 23.03.03.080---
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023; 23.03.03.081---
Infection11.01.08.002---
Instillation site pain08.02.01.008; 12.07.01.008---
Muscle spasms15.05.03.004--
Nasopharyngitis11.01.13.002; 22.07.03.002---
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene